» Articles » PMID: 19692652

MEK, P38, and PI-3K Mediate Cross Talk Between EGFR and TNFR in Enhancing Hepatocyte Growth Factor Production from Human Mesenchymal Stem Cells

Overview
Specialties Cell Biology
Physiology
Date 2009 Aug 21
PMID 19692652
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Human bone marrow mesenchymal stem cells (MSCs) are a potent source of growth factors, which are partly responsible for their beneficial paracrine effects. We reported previously that transforming growth factor-alpha (TGF-alpha), a putative mediator of wound healing and the injury response, increases the release of vascular endothelial growth factor (VEGF), augments tumor necrosis factor-alpha (TNF-alpha)-stimulated VEGF production, and activates mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI-3K) pathway in human MSCs. The experiments described in this report indicate that TGF-alpha increases MSC-derived hepatocyte growth factor (HGF) production. TGF-alpha-stimulated HGF production was abolished by inhibition of MEK, p38, PI-3K, or by small interfering RNA (siRNA) targeting TNF receptor 2 (TNFR2), but was not attenuated by siRNA targeting TNF receptor 1 (TNFR1). Ablation of TNFR1 significantly increased basal and stimulated HGF. A potent synergy between TGF-alpha and TNF-alpha was noted in MSC HGF production. This synergistic effect was abolished by MEK, P38, PI-3K inhibition, or by ablation of both TNF receptors using siRNA. We conclude that 1) novel cross talk occurs between tumor necrosis factor receptor and TGF-alpha/epidermal growth factor receptor in stimulating MSC HGF production; 2) this cross talk is mediated, at least partially, via activation of MEK, p38, and PI-3K; 3) TGF-alpha stimulates MSCs to produce HGF by MEK, p38, PI-3K, and TNFR2-dependent mechanisms; and 4) TNFR1 acts to decrease basal TGF-alpha and TNF-alpha-stimulated HGF.

Citing Articles

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.


Growth factors and growth factor gene therapies for treating chronic wounds.

Mullin J, Rahmani E, Kiick K, Sullivan M Bioeng Transl Med. 2024; 9(3):e10642.

PMID: 38818118 PMC: 11135157. DOI: 10.1002/btm2.10642.


Immunomodulation of Skin Repair: Cell-Based Therapeutic Strategies for Skin Replacement (A Comprehensive Review).

Tavakoli S, Kisiel M, Biedermann T, Klar A Biomedicines. 2022; 10(1).

PMID: 35052797 PMC: 8773777. DOI: 10.3390/biomedicines10010118.


The role of hepatocyte growth factor in mesenchymal stem cell-induced recovery in spinal cord injured rats.

Song P, Han T, Xiang X, Wang Y, Fang H, Niu Y Stem Cell Res Ther. 2020; 11(1):178.

PMID: 32410702 PMC: 7227078. DOI: 10.1186/s13287-020-01691-x.


Genetic correction of Werner syndrome gene reveals impaired pro-angiogenic function and HGF insufficiency in mesenchymal stem cells.

Tu J, Wan C, Zhang F, Cao L, Law P, Tian Y Aging Cell. 2020; 19(5):e13116.

PMID: 32320127 PMC: 7253065. DOI: 10.1111/acel.13116.


References
1.
Nakamura T . Structure and function of hepatocyte growth factor. Prog Growth Factor Res. 1991; 3(1):67-85. DOI: 10.1016/0955-2235(91)90014-u. View

2.
Hamilton M, Wolfman A . Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor. J Biol Chem. 1998; 273(43):28155-62. DOI: 10.1074/jbc.273.43.28155. View

3.
Min J, Lee Y, Kim J, Kim Y, Kim S, Lee S . Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res. 2005; 96(3):300-7. DOI: 10.1161/01.RES.0000155330.07887.EE. View

4.
Barrandon Y, Green H . Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell. 1987; 50(7):1131-7. DOI: 10.1016/0092-8674(87)90179-6. View

5.
Duan H, Wu C, Wu D, Lu Y, Liu H, Ha X . Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther. 2003; 8(3):467-74. DOI: 10.1016/s1525-0016(03)00186-2. View